De-Identified Health Data Market Report 2026

The de-identified health data market size has grown rapidly in recent years. It will grow from $9.2 billion in 2025 to $10.31 billion in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to increasing adoption of electronic health records, rising demand for population health analytics, expansion of clinical research databases, growing focus on patient privacy compliance, increasing availability of structured healthcare data.

The de-identified health data market size is expected to see rapid growth in the next few years. It will grow to $16.07 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to growing use of ai-driven health insights, rising investments in precision medicine research, expansion of value-based care analytics, increasing demand for secure health data exchange, wider adoption of real-world evidence in regulatory decisions. Major trends in the forecast period include expansion of large-scale de-identified data platforms, growing use of real-world evidence analytics, rising demand for privacy-preserving data sharing models, increased adoption of longitudinal patient data analysis, integration of multi-source healthcare datasets.

The growing adoption of electronic health records (EHRs) is anticipated to accelerate the expansion of the de-identified health data market in the coming years. Electronic health records are digital repositories of a patient’s complete medical history, encompassing diagnoses, treatments, medications, laboratory results, and other health information that can be securely stored and shared among authorized healthcare providers. Their adoption is increasing because they improve patient care and safety by providing accurate, real-time access to comprehensive medical information. De-identified health data further strengthens electronic health records by supporting secure data exchange and advanced analytics while safeguarding patient privacy, which ultimately enhances clinical decision-making and healthcare outcomes. For example, in August 2025, according to the National Center for Biotechnology Information, a US-based National Library of Medicine (NLM) within the U.S. National Institutes of Health (NIH), it was reported in 2024 that most hospitals had implemented patient engagement features allowing patients to electronically view (99%) items such as test results, download (96%), and transmit their health information to third parties (84%). As a result, the increasing adoption of electronic health records is contributing significantly to the growth of the de-identified health data market.

Leading companies in the de-identified health data market are concentrating on the development of advanced solutions, including real-world biomarker coverage applications, to support evidence-based healthcare decisions. A real-world biomarker coverage application uses de-identified patient data to track and evaluate biomarker trends and effectiveness across diverse populations outside of clinical trial settings, enabling researchers and healthcare providers to better understand treatment responses and disease patterns. For instance, in July 2025, Datma Inc., a US-based healthcare technology company, launched the Federated Biomarker Explorer, a free application designed to help pharmaceutical teams rapidly validate real-world biomarker coverage across Datma’s federated network of participating data contributors. The tool delivers aggregate, cohort-level insights into biomarker availability, allowing teams to quickly assess coverage without requiring contracts or IT support. It also supports secure integration of users’ own data for overlap analysis and enables early-stage feasibility assessments using clinical and demographic filters, helping organizations determine whether datasets include the required patient populations before allocating resources.

In July 2025, Datavant Inc., a US-based health information technology company, acquired Aetion Inc. for an undisclosed sum. With this acquisition, Datavant seeks to strengthen its real-world evidence (RWE) capabilities by combining Aetion’s advanced analytics platform with its existing offerings, providing life sciences and healthcare organizations with a comprehensive, end-to-end solution for producing regulatory-grade insights from de-identified health data. Aetion Inc. is a US-based real-world evidence platform that delivers de-identified health data services through solutions such as Aetion Generate.

Major companies operating in the de-identified health data market are UnitedHealth Group Incorporated, Oracle Corporation, IQVIA Holdings Inc, ICON Public Limited Company, Datavant Inc, Premier Inc., iMerit Technology Services Pvt. Ltd., Tempus Labs Inc., Medidata Solutions Inc., Veradigm Inc., Flatiron Health, Merative LP, Komodo Health Inc., Shaip Inc., Truveta Inc., Evidation Health Inc., TriNetX Inc., Clarify Health Solutions Inc., Akrivia Health Ltd., Gradient Health Inc.

North America was the largest region in the de-identified health data market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the de-identified health data market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the de-identified health data market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the de-identified health data market by increasing costs associated with imported cloud infrastructure hardware, data storage systems, cybersecurity solutions, and advanced analytics platforms used to process large healthcare datasets. Healthcare research organizations and pharmaceutical companies in North America and Europe are most affected due to reliance on imported high-performance computing and security components, while Asia-Pacific faces rising costs for data center expansion. These tariffs are increasing operational expenditures and slowing infrastructure scaling initiatives. However, they are also encouraging regional cloud deployment, domestic cybersecurity development, and localized health data processing ecosystems that improve long-term data sovereignty and compliance.

The de-identified health data market research report is one of a series of new reports that provides de-identified health data market statistics, including de-identified health data industry global market size, regional shares, competitors with a de-identified health data market share, detailed de-identified health data market segments, market trends and opportunities, and any further data you may need to thrive in the de-identified health data industry. This de-identified health data market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

De-identified health data refers to patient information from which all personally identifiable elements, such as names, addresses, and social security numbers, have been removed, ensuring that the data cannot be traced back to any individual. This enables healthcare providers, researchers, and organizations to study patterns, improve treatment approaches, and develop effective public health initiatives while maintaining patient confidentiality.

The primary categories of de-identified health data include clinical data, genomic data, patient demographic information, prescription data, hospital and provider data, and pharmacogenomic data. Clinical data encompasses health-related information gathered during healthcare delivery, such as medical histories, diagnoses, treatments, laboratory findings, and outcomes. These services are utilized across a wide range of applications, including clinical research and trials, public health initiatives, precision medicine, health economics and outcomes research (HEOR), population health management, drug discovery and development, healthcare quality enhancement, insurance underwriting and risk evaluation, and others, serving end users such as pharmaceutical and biotechnology companies, healthcare providers, insurance companies or healthcare payers, research organizations, government bodies, and others.

The de-identified health data market includes revenues earned by entities by providing services such as medical research and clinical studies, machine learning development, public health and epidemiology, healthcare system improvement, and health economics and policy planning. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.